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Introduction: Stereotactic body radiation therapy (SBRT) is an area of active investigation
for treatment of prostate cancer. In our phase I dose-escalation study, maximum-tolerated
dose (MTD) was not reached, and subsequently phase II study has been completed. The
purpose of this article is to review our experiences of dose-escalated SBRT for localized
prostate cancer.
Methods and materials: Patients enrolled to phase I/II study from 2006 to 2011 were
reviewed. Prescription dose groups were 45, 47.5, and 50 Gray (Gy) in five fractions over
2.5 weeks. Toxicity and quality of life questionnaire data were collected and analyzed.
Descriptive statistics were obtained in the form of means, medians, and ranges for the
continuous variables, and frequencies and percentages for the categoric variables.
Results: Ninety-one patients were enrolled from five institutions. Median follow-up for
prostate specific antigen (PSA) evaluation was 42 months. PSA control remains at 99%.
While the MTD was not reached in the phase I study, excess high grade rectal toxicity
(10.6%) was noted in the phase II study. The 13 patients treated to 50 Gy in the phase I
study that did not have high grade rectal toxicity, in retrospect met these parameters and
have not had further events on longer follow-up.
Conclusion: Prostate specific antigen control rate, even for patients with intermediate
risk, is thus far excellent at these dose levels. This study provides a platform for explo-
ration of SBRT based clinical trials aimed at optimizing outcome for intermediate and high
risk patients. High grade toxicities specifically related to the rectum were observed in a
small but meaningful minority at the highest dose level. Dose constraints based on physio-
logic parameters have been defined to mitigate this risk, and strategies to minimize rectal
exposure to such doses are being explored.
Keywords: SBRT, prostate cancer, rectal toxicity, low risk, intermediate risk
INTRODUCTION
Stereotactic body radiation therapy (SBRT)/Stereotactic ablative
radiotherapy (SABR) remains an area of active investigation for
prostate cancer research. Most recently,we have completed a multi-
institutional phase I and II study of SBRT for low and intermediate
risk prostate cancer patients (1,2). Our study was unique on several
fronts. First of all, it was a multi-institutional design, and patients
were enrolled from five different institutions using a broad variety
of radiation delivery platforms. Secondly, it involved a prospec-
tive dose-escalation phase I study design that enrolled at least 15
patients per dose level. Third, this study involved use of doses that
are significantly higher than what has been typically reported for
use in the retrospective prostate SBRT literature. Finally, our expe-
rience of an unexpected change in toxicity profile from phase I to
the phase II findings, highlights the importance of conducting a
prospectively designed phase II study to better assess the efficacy
and safety of what is determined to be the maximum-tolerated
dose (MTD) from a limited number of patients in the phase I
efforts (2). In this article, we will briefly update readers of our expe-
riences, including informing readers of potential for rectal toxicity
when considering use of ablative radiation doses for tumors near
bowel structures, and discuss potential implications when con-
ducting future clinical trial design of high-dose SBRT for prostate
cancer.
MATERIALS AND METHODS
PATIENTS AND ELIGIBILITY
From 2006 to 2011, 91 patients were enrolled to an institutional
review board (IRB) – approved multi-institutional phase I/II clin-
ical study, and analyzed. At the time of study design, it was
determined that this would be a phase I/II study, and therefore
pooling of data between the two studies was anticipated. This
study was registered with National Cancer Institute, and clinical-
Trials.gov identifier is NCT00547339. Please see patient eligibility
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section in prior publication (1). The only change from eligibility
criteria in the phase II component was exclusion of patients who
are actively immune-suppressed due to safety concerns (1).
STATISTICAL DESIGN
Phase I study design
This study was designed as a prospective dose-escalation study.
The goal was to escalate the dose of five-fraction SBRT to the
MTD or 50 Gray (Gy). Dose-limiting toxicity (DLT) was defined
as grade 3–5 gastrointestinal (GI), genitourinary (GU), sexual, or
neurologic toxicity attributed to therapy occurring within 90 days
of registration using Common Terminology Criteria of Adverse
Events version 3 (CTCAE v3.0). Escalation was allowed to occur
if four or fewer patients within a cohort of 15 patients experi-
enced DLT within 90 days of follow-up at a given dose level. This
escalation rule is the same as the traditional 3+ 3 design in which
<33% DLT rate at the current dose level leads to further dose esca-
lation. Using a larger number of patients per dose level is justified
for this trial on the basis of the previously referenced SBRT and
high-dose rate (HDR) experiences that predict efficacy even with
the starting dose. As with the traditional 3+ 3 design, sequential
enrollment served as a protection to limit potential overdosing.
Furthermore, 15 patients at each level allowed us to more accu-
rately estimate the DLT rate and to study other end points related
to the enrolled patients. The MTD was defined as the dose level
immediately below the intolerable dose.
Toxicity stopping rules for phase II component
Three interim analyses of toxicity were planned after 25% (12
patients), 50% (24 patients), and 75% (36 patients) of the total
number of evaluable patients to be accrued in phase II. These
interim analyses were done after patients finished their toxicity
assessment periods for each group (i.e., 90 days of post ther-
apy follow-up). The following early stopping rules reject the null
hypothesis that the toxicity rate is≤10% in favor of the alternative
hypothesis that the toxicity rate is at least 30% with an overall Type
I error rate of no more than 0.05:
six or more cases of unacceptable toxicities out of the first 12
evaluable patients, or
seven or more cases of unacceptable toxicities out of the first 24
evaluable patients, or
eight or more cases of unacceptable toxicities out of the first 36
evaluable patients.
The final analysis tested the same null hypothesis using the
rejection rule of 10 or more patients with unacceptable toxici-
ties out of the total sample of 47 evaluable patients. This insured
an overall significance level of 0.05 for the final conclusion. After
47 of the 50 accrued patients were evaluable, then the first 47
evaluable patients were used for this analysis. If the number of
unacceptable toxicities observed demonstrate via the monitor-
ing rules above that the treatment-related unacceptable toxicity
rate is 30% or more, consideration was made for stopping the
study. In this case, the study chair, study principal investigators
(PIs), and statistician reviewed the toxicity data along with the
Data Safety Monitoring Committee (DSMC) and made appropri-
ate recommendations about continuing the study. Additionally,
the treatment-related unacceptable toxicity rates were monitored
during the 5-year follow-up period. If the unacceptable toxic-
ity rate exceeded 30% at any time during the 5-year follow-up
period, the study chair, study PIs, and statistician would review
the toxicity data along with the DSMC and make appropriate
recommendations about reporting the information.
In the phase II study, all patients were treated with 10 Gy
per fraction to a total dose of 50 Gy. Otherwise, planning and
treatment was described previously (1).
Study end points and statistics
Study end points. In the phase I study, the primary endpoint was
to determine MTD. Secondary end points were late toxicity (occur-
ring 90 days from treatment), patient-reported toxicity/Quality of
Life (QOL), and prostate specific antigen (PSA) response. The
Expanded Prostate Cancer Index Composite (EPIC) question-
naire and American Urological Association (AUA) symptom scores
were collected at baseline and at 1.5, 3, 12, and 18 months after
treatment. Patients were observed with PSA, history, and physi-
cal examination every 3 months for the first year, every 6 months
for years two to three, and yearly starting 4 years after treatment.
The nadir +2 ng/mL failure definition was used for biochemical
control.
The phase II component of this study was designed to test
whether late GU/GI toxicity is above 10%. The sample size for
phase II was determined so that the probability of rejecting the
treatment because of excessive late toxicity was 90% if the true
late toxicity rate is 23% or higher. Assuming an exponential dis-
tribution for time from the end of the acute period (270 days) to
the occurrence of late toxicity, the hazard rate for the expected
10% toxicity rate, and the unacceptable 23% toxicity rate was
0.006/month and 0.015/month, respectively. Following the asymp-
totic property of the observed hazard and using Z -test for the
logarithm of the hazard ratio, 12 cases with severe late GU/GI
toxicity would be required. Thus, 47 patients were required to be
accrued within 3–4 years and be followed for 270 days after the
acute period (i.e., a total of 540 days) to have a statistical power of
90% with a one-sided significance level of 0.05. Considering 5%
ineligible cases and lack-of-data cases, the sample size of the phase
II component of this study was planned to be 50 patients. With
the data for the 47 patients from Phase II trial plus an additional
44 patients from the previously conducted Phase I trial, our total
sample size in this analysis is 91. Patients from both trials were
recruited from multiple institutions.
Descriptive statistics were obtained in the form of means, medi-
ans, and ranges for the continuous variables, and frequencies and
percentages for the categorical variables. All statistical analyses
were performed at the 0.05 significance level using SAS 9.2 for
Windows (SAS Institute Inc., Cary, NC, USA).
PLANNING AND TREATMENT
Planning, setup, and dose parameters for the clinical trial
Fiducial markers consisting of gold seeds (Calypso beacons were
permitted) were placed within the prostate approximately 1 week
before radiation simulation. A bowel regimen consisting of 30 mL
of milk of magnesia the evening before and a Fleet enema 30–
60 min before simulation and each treatment was used, along
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with the insertion of a 60–100 cm3 rectal balloon. Patients were
instructed to have a full bladder for simulation and treatment. A
thin, flexible catheter was used to delineate the urethra at simula-
tion only. Magnetic resonance imaging (MRI) and/or computed
tomography (CT) was used to define the prostate and organs at
risk. The prostate was expanded uniformly by 2–3 mm to cre-
ate the planning target volume (PTV) based on institutional PTV
guidelines. SBRT was delivered via ring gantry helical accelerator
(Tomotherapy; TomoTherapy Inc., Madison, WI, USA) or on a
linear accelerator with image guidance (Trilogy; Varian Medical
Systems, Palo Alto, CA, USA and Synergy; Elekta AB, Stock-
holm, Sweden) with energies of 6–15 MV. None of the centers
used a Cyberknife platform to treat enrolled patients, mostly
related to availability or arbitrary preferences. Intensity modu-
lated radiotherapy (IMRT) was utilized in all cases. The dose was
prescribed to cover 95% of the PTV. Rapid dose fall-off outside
the PTV was prioritized over PTV dose uniformity, resulting in
considerable dose heterogeneity within the PTV. Tissue hetero-
geneity correction was used in all cases. A rectal balloon was used,
which helped push the lateral and posterior walls away from the
high-dose region, which at the time of trial design, was felt to
be advantageous for sparing stem cells whose migration would
be required to help heal the anterior rectal wall after radiation
therapy. The rectal wall was divided and separately contoured
into anterior, lateral, and posterior walls in the region of the
PTV. The anterior wall was allowed to receive no more than
105% of the prescription dose. No more than 3 cm3 of the lat-
eral walls were allowed to receive 90% of the prescription dose.
The posterior rectal wall maximum dose was limited to 45%
of the prescription dose. The bladder wall (outer 5 mm of the
entire bladder contour) was limited to 105% of the prescrip-
tion dose with no more than 10 cm3 receiving 18.3 Gy or greater.
The maximum prostatic urethra dose was limited to 105% of the
prescription dose.
TOXICITY
Toxicity events and ongoing cumulative toxicity reports from all
institutions were reviewed at regular intervals by the Simmons
Comprehensive Cancer Center DSMC and an independent med-
ical monitor with prostate cancer expertise. Common Terminol-
ogy Criteria of Adverse Events (CTCAE) version 3.0 was used.
Acute and delayed toxicity were defined a priori on the clinical
study protocol, as toxicity occurring <270 days and occurring or
persisting≥270 days from start of protocol treatment, respectively.
If the number of unacceptable toxicities observed demonstrate
via the monitoring rules that the treatment-related unaccept-
able toxicity rate is 30% or more, consideration was made for
stopping the study. The study chair, PIs, and statistician would
review the toxicity data along with the DSMC to make appropriate
recommendations about continuing the study.
RESULTS
PATIENT CHARACTERISTICS
Total of 91 patients were eligible for analysis for this study, includ-
ing 44 in the phase I study, and 47 in the phase II study. Initially
45 patients were enrolled in the phase I study, but 1 patient was
deemed ineligible upon re-review of his pathology demonstrating
Gleason 9 features. This patient was omitted from further analysis.
Complete list of patient characteristics for phase I and II studies
have previously been published (1, 2). Our study enrolled from
three institutions during the phase I study, and this was expanded
to five institutions during the phase II study. As seen in Table 1,
of the five institutions, four are academic centers, and one is a
community practice. While majority of the patients (64%) for the
two studies were enrolled from the PIs institution (UT Southwest-
ern, Dallas, TX, USA), a significant number of patients enrolled in
the two studies (36%) came from the other four institutions. The
study did permit multiple platforms for treatment modality to be
used, with three of the five centers using Tomotherapy platform,
while the other two used standard linear accelerator technology to
perform the SBRT.
PSA CONTROL
Median f/u for PSA evaluation for all patients was 42 months (m)
[range (r) 1.5–84 months]. For phase I study, median f/u for PSA
evaluation was 54 months (r 3–84 m). For phase II study, median
f/u for PSA evaluation was 36 m (r 1.5–60 m). Median f/u for PSA
evaluation for patients treated to 45 Gy was 60 m (r 3–84 m), to
47.5 Gy was 54 m (r 30–72 m), and to 50 Gy (phase I study) was
54 m (r 3–60 m). PSA control rate to date is 99% as only 1 patient
(out of 91) has demonstrated failure to therapy. This patient has
Gleason score (GS) 4+ 3 (<50% core involvement), pretreatment
PSA 7.4, and cT2b intermediate risk disease (or unfavorable inter-
mediate risk by Memorial Sloan Kettering criteria). This patient
was treated on the 45 Gy arm of the phase I study. On evalua-
tion, he was found to have regional (imaging and biopsy proven
external iliac nodal failure) 41 months from time of initiation of
SBRT. He subsequently developed L3 bone metastases 45.5 months
post initiation of therapy. At the time of biochemical failure, he
also underwent prostate biopsy, which demonstrated two micro-
scopic foci of residual prostatic adenocarcinoma at the right base,
which was too miniscule to be accurately given a Gleason grade. He
was eventually started on salvage systemic therapy 46 months post
SBRT. If we consider only the 9 Gy× 5 fraction group, PSA control
rate in this group is 93.3% with a median f/u of 60 months. If we
consider by Gleason grade, PSA control is 100% in patients with
GS 6 or 3+ 4 disease, and 93.3% in GS 4+ 3 patients. Figure 1A
illustrates the mean PSA trend changes for patients treated in the
different arms of the study showing no obvious difference in PSA
trends between these groups. Figure 1B demonstrates PSA trends
for all patients treated on this study. As can be seen, on the aver-
age, patients had >50% reduction from their baseline PSA values
within first 6 months, followed by steady decline over the next
3 years.
RECTAL TOXICITY IN THE 50 Gy GROUP: PHASE I VS. PHASE II
EXPERIENCE
We have recently reported on our rectal toxicity outcome from the
phase I/II study (2). What is most remarkable from our experi-
ences was that our toxicity profile was markedly different in the
phase II experience despite having 15 patients treated at each dose
level in the phase I study (which is far larger than typical number
of patients treated per dose level for phase I drug trials). As seen in
Table 2, only 1 out of 14 patients developed grade 3+ rectal toxicity
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Table 1 | Patient enrollment by institutions.
Institution 45Gy 47.5Gy 50Gy Phase II Total Treatment platform used
University of Texas Southwestern Medical
Center, Dallas, TX, USA
14 8 9 27 58 LINAC
University of Minnesota, Minneapolis, MN, USA 1 4 4 11 20 Tomotherapy
Prairie Lakes Hospital, Watertown, SD, USA 3 1 4 Tomotherapy
University of Colorado, Denver, CO, USA 7 7 LINAC
University of Florida Health Cancer
Center-Orlando (previously known as MD
Anderson – Orlando)
2 2 Tomotherapy
Total 15 15 14 47 91
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FIGURE 1 | Plot of mean fold change in PSA compared to baseline levels (A) by individual dose groups and (B) for all patients. S.E., standard error; PSA,
prostate specific antigen; Gy, gray.
Table 2 |Worst acute and delayed rectal toxicity in patients treated to 50Gy dose in phase I and phase II studies.
Rectal toxicity All patients (n=91) 50Gy phase I (n=14) 50Gy phase II (n=47)
Grade Acute No. (%) Late No. (%) Acute No. (%) Late No. (%) Acute No. (%) Late No. (%)
0 39 (42.9) 38 (41.8) 5 (35.7) 5 (35.7) 18 (38.3) 15 (32)
1 33 (36.3) 27 (29.7) 7 (50) 6 (43) 16 (34) 15 (32)
2 17 (18.7) 21 (23.1) 2 (14.3) 2 (14.3) 11 (23.4) 13 (27.7)
3 1a (1.1) 3 (3.3) 0 (0) 0 (0) 1a (2.1) 3 (6.4)
4 1 (1.1) 2 (2.2) 0 (0) 1 (7.1) 1 (2.1) 1 (2.1)
Number of patients w/grade 3+ toxicity 6 (6.6%) 1 (7.1%) 5 (10.6%)
aFor this patient, toxicity occurred on day 225 (acute period), but persisted to day 470, well into the delayed toxicity time period. Therefore, this patient was reported
as having high grade acute and delayed toxicity. While seven total toxicities are reported, this occurred in a total of six patients.
in the phase I study. As discussed previously, this patient was on
immunosuppressants due to history of kidney transplantation.
Given that only one patient developed serious rectal toxicity in all
of the phase I study groups, there was strong suspicion that this
event may have been related to the chronic immune-suppressed
state of this patient. Regardless, MTD was not reached in the phase
I study, and a decision was made to proceed to the phase II study
using this dose, with the exclusion of patients on immunosup-
pression (1). However, in the phase II study, the toxicity profile
changed, and five patients (10.6%) developed high grade rectal
toxicity at the time of data analysis with a median follow-up of
24.5 months. Of these total six patients, five had issues involving
the anterior rectum, all of whom underwent a diverting colostomy,
and for details, we refer readers to our recent manuscript’s Table 3,
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Table 3 | Stereotactic body radiation therapy studies.
Study N Risk group
(% of sample size)
Total dose
(Gy)
Fraction size
(Gy)
Median follow-up
(months)
Biochemical
control (%)
Grade 3+ GI
toxicity
Katz (3) 304 LR 69 35–36.25 7–7.25 60 LR 97 0%
IR 27 IR 90.7
HR 4 HR 74.1
King (4) 1100 LR 58 35–40 7–8 36 LR 95 NR
IR 30 IR 83
HR 11 HR 78
McBride (5) 45 LR 100 36.25–37.5 7.25–7.5 44.5 97.7 5%
Oliai(6) 70 LR 51 35–37.5 7–7.5 27–33 LR 100 0%
IR 31 IR 95
HR 17 HR 77.1
Chen (7) 100 LR 37 35–36.25 7–7.25 27.6 99 0%
IR 55
HR 8
This study 91 LR 36 45–50 9–10 42 LR 100 6.6%
IR 64 IR 98
All 99
30 LR 37 45–47.5 9–9.5 54 96.7 0%
IR 63
61 LR 36 50 10 24.5 100 9.8%
IR 64
LR, low risk; IR, intermediate risk; HR, high risk; GI, gastrointestinal.
which details these issues (2). Of note, one of these patients had
a posterior Dieulafoy lesion, which was cauterized and resolved
next day. While we did not feel that this case was related to the
SBRT, but as the patient did require hospitalization, was docu-
mented as a high grade rectal event in our study (2). While we
await full reporting of toxicity data from the next interim analysis
with longer follow-up, we are as of yet aware of only one addi-
tional patient that has developed high grade delayed rectal toxicity
within the phase II group (12.8%), and the full data from the
phase II experience will be reported in future publications. Fur-
thermore, we have determined potential causal mechanisms for
this rectal injury, and published our findings on predictors of rec-
tal tolerance to five fraction SBRT (2). Remarkably, even with the
longest follow-up of the high-dose experience, no additional high
grade rectal toxicity has developed in the 13 patients that were
treated to 50 Gy in the phase I study. It appears that even with
longer follow-up, the results from our phase I study would not
have given us any additional indication that our MTD would have
been anything <50 Gy for the phase II study.
BOWEL QUALITY OF LIFE OUTCOME IN THE 50 Gy GROUP: PHASE I VS.
PHASE II EXPERIENCE
All patients in this study were required to undergo health related
QOL questionnaires at baseline, and then at 1.5, 3, 12, and
18 months post SBRT. The EPIC questionnaires were used for this
analysis. Given the discrepancy in the toxicity findings, we have
further analyzed EPIC-Bowel symptom scores from patients who
underwent 50 Gy in five fractions in the phase I (n= 14) and phase
II (n= 47) study. Overall compliance to questionnaires was very
good particularly early on in the study. Hundred percent and 96%
of patients filled out baseline questionnaires in the phase I and
II groups, respectively. By 18 months, data for EPIC-Bowel ques-
tionnaires were available from 78.5 to 53% in the phase I and II
groups, respectively. As seen in Figure 2, the mean scores were
fairly similar at 1.5 and 3 months post therapy with initial drop
at 1.5 months followed by recovery at 3 months, reflective of acute
toxicity events. However at 12 and 18 months, mean scores were
lower in the patients treated in the phase II study, which may in
part be due to the worse rectal toxicity noted in this group. In both
groups, the EPIC-Bowel scores improved at 18 months compared
to 12 months after treatment.
DISCUSSION
We have reported some of our interim findings from our phase
I/II multi-institutional study of dose-escalated SBRT for localized
prostate cancer. In the setting of a prospective, multi-institutional
effort, we have treated patients starting at 45 Gy in five fractions
to 50 Gy in five fractions, a dose that has been rarely reported in
other series. Our prostate cancer control outcome in this study
is excellent at 99% with a reasonable median f/u of 42 months.
Of note, 53% of all patients in this study were GS 7, with 16.4%
being GS 4+ 3. Interestingly, although we have only had one fail-
ure, this occurred in a patient who had GS 4+ 3 features. While
we believe that his treatment failure was most likely attributable
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FIGURE 2 | Expanded prostate cancer index composite-bowel
summary score for patients treated in the 50Gy dose group for the
phase I and phase II studies. EPIC, expanded prostate cancer index
composite; Gy, gray.
to regional biopsy proven nodal recurrence (3.4 years post ther-
apy), it was intriguing to see that on prostate biopsy, there were
concerns of two microscopic foci of residual prostatic adenocar-
cinoma 3.4 years post SBRT therapy even after 9 Gy× 5 fraction
in this patient. While this pathologic data did not demonstrate a
convincing evidence of local persistence of disease, it does give us
a pause to consider that there may be certain aggressive subset of
prostate tumors that can resist even doses as high as 9 Gy× 5 frac-
tions, particularly for higher grade tumors. Interestingly, pooled
analysis of SBRT experiences delivering median dose of 36.25 in
4–5 fractions suggested worse PSA outcome for intermediate and
high risk disease with 5 years biochemical relapse free survival of
84 and 81%, respectively, compared to 95% for low risk patients
(4). Similar findings were seen in study by Katz et al., with 5-year
biochemical recurrence free survival reported to be 97, 90.7, and
74.1% for low, intermediate, and high risk patients, respectively
(3). While some of these intermediate and high risk patients did
receive doses as high as 38–40 Gy in five fractions (4), no published
studies to date have reported doses in the order of 45–50 Gy as was
the case in our study. Interestingly, in our study, patients treated
with ≥47.5 Gy in five fractions, thus far have a 100% PSA control
rate. This is the case even for patients in the 47.5 Gy group that have
a respectable median f/u of 53 months (range 1.4–59.2 months).
Of note, 7/15 patients in the 47.5 Gy group had GS 7 features, and
30/31 patients in the 50 Gy group had GS 7 features suggesting
that local control was well maintained even in the intermediate
risk patients using these higher doses.
However, our study,despite excellent PSA outcome, has demon-
strated that there can be a risk of serious rectal injury at
higher doses unless rectal constraints to limit vasculature/stromal
destructive effects and to maintain a reasonable migration length
to permit stem cell rescue of injured rectal mucosa are respected.
We have specifically published on our findings that high grade
rectal events were correlated with volume of rectal wall receiving
50 Gy> 3 cm3, and treatment of >35% of rectal wall to 39 Gy
(2). What is remarkable from our phase I/II experience was that
even when a respectable number of patients were treated in the
50 Gy of the phase I arm (n= 14), it required a larger sample size
(n= 47) before it became apparent that we have reached a limit
for rectal tolerance. This is reflected in the poorer QOL, and tox-
icity profile outcome (Table 2; Figure 2) in the patients treated
in the phase II study vs. the 50 Gy arm of the phase I study. This
is a sobering reminder to all of us that anecdotal experience of
handful of patients should not suffice to give comfort when con-
sidering non-established treatments, and that properly designed
prospective studies with adequate sample size are required when
considering novel dose-escalated therapeutic approaches. What is
apparent from our analysis was that such toxicity may be avoided
if we follow the dose constraints discovered through this process
(2), and that in the phase I study, 13 of the 14 patients happened
to have met the dose constraints required to minimize high grade
rectal events, most likely by chance.
Table 3 compares our experiences to some of the more contem-
porary studies with larger sample sizes that have been reported in
the literature, including the consortium study (3–7). It is appar-
ent that our outcome is comparable in terms of PSA control, all
in support of the growing body of evidence that SBRT appears
to be an effective treatment for low to intermediate risk prostate
cancer. While studies do seem to support the use of 35–36.25 Gy
for low risk patients, many of these are non-prospective studies.
Our experience based on a rigorously designed and tested prospec-
tive trial, with a phase I dose-escalation scheme leading into the
phase II study. Based on our findings thus far, we believe that 45–
47.5 Gy is a safe and effective dose for further clinical studies. We
do believe that longer follow-up would be required particularly for
intermediate risk patients for all these studies including ours, to
determine the potential merits or detriments of the higher doses
used in our study. To further minimize rectal dose for future stud-
ies of SBRT, we are also exploring the use of an absorbable rectal
spacer in conjunction with SBRT for our next studies involving low
and intermediate risk patients (8). Furthermore, although addi-
tional long term follow-up data of patients treated at 45–47.5 Gy is
warranted, given the paucity of further rectal issues on long term
follow-up, and given the relative ease by which we can respect rec-
tal dose constraints discovered from our analysis (2), we believe
that these doses should prove to be safe, and possibly more potent
and effective for patients with higher grade tumors. We are there-
fore using our experiences as a platform to develop clinical trials
aimed at optimizing SBRT for patients with high risk prostate can-
cer who may require doses higher than currently reported in the
literature (3, 4).
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